Chinese Vaccine Leader Sinovac Starts Preparations To Produce H1N1 Vaccine
This article was originally published in PharmAsia News
You may also be interested in...
Hutchison MediPharma's Solid Tumor Drug First Oncology Project To Enter SFDA Fast-track Approval
SHANGHAI - China's State FDA held a pre-IND meeting June 17 with Shanghai-based Hutchison MediPharma on its Phase I development plan for its solid tumor drug HMPL-012, the company told PharmAsia News
Hutchison MediPharma's Solid Tumor Drug First Oncology Project To Enter SFDA Fast-track Approval
SHANGHAI - China's State FDA held a pre-IND meeting June 17 with Shanghai-based Hutchison MediPharma on its Phase I development plan for its solid tumor drug HMPL-012, the company told PharmAsia News
Baxter Expanding Facilities In China To Keep Pace With Exploding Market Growth, Testing A/H1N1 Strain In U.S. For Potential Vaccine
BEIJING - The U.S.-headquartered Baxter International is reinvesting most of the $200 million in revenues it posted in China in 2008 to expand production facilities across the country, even as Baxter's American scientists begin testing a strain of the A/H1N1 virus for a potential vaccine if a pandemic is declared by the World Health Organization